The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...

Avant Technologies Inc shares O.AVAI are trading -0.07 at $0.64.

LAS VEGAS, NV / / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ('Avant' or the 'Company'), and its partner, Ainnova Tech, Inc., (Ai ...

Along with its partner, Ainnova Tech, Inc, today announced the selection of Fortrea, a global provider of clinical development solutions to the life sciences industry, as the contract research ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

LAS VEGAS, NV / ACCESS Newswire / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology ...

AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and automation, the reality is that many of us have been integrating AI into our ...

Sienna Eye Care will provide personalized solutions for eye conditions such as dry eyes, glaucoma, macular pediatric degeneration and diabetic retinopathy. It also will provide pediatric evaluations ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.